Ibio Inc (NYSEAMERICAN:IBIO) had a decrease of its short interest by 12.1%. In April was published IBIO’s total 413,500 short interest by FINRA. That’s 12.1% down from 470,400 shares. Ibio Inc (NYSEAMERICAN:IBIO) has 74,800 shares average volume. It’ll cost 6 days for IBIO to recover its former position. 25.53% is Ibio Inc float short.

IBIO is hitting $0.8 during the last trading session, after decreased 2.74%.iBio, Inc. has volume of 32,351 shares. Since April 7, 2018 IBIO has declined 57.16% and is downtrending. IBIO underperformed by 61.53% the S&P 500.

iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally.The company has $15.23 million market cap. The Company’s lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases.Currently it has negative earnings. It is also developing vaccine candidates for third parties.

There’s a significant iBio, Inc. (NYSEAMERICAN:IBIO) news announced by Globenewswire.com. It’s an item titled: “iBio Announces Appointment of Thomas F. Isett to Board of Directors – GlobeNewswire” on April 01, 2019.